Author:
Tile Lianne,Cheung Angela M.
Publisher
Springer International Publishing
Reference83 articles.
1. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62.
2. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(10):1910.
3. Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60(4):324–33.
4. Khan M, Cheung AM, Khan AA. Drug-related adverse events of osteoporosis therapy. Endocrinol Metab Clin N Am. 2017;46(1):181–92.
5. Lewiecki EM, Miller PD, Harris ST, Bauer DC, Davison KS, Dian L, et al. Understanding and communicating the benefits and risks of Denosumab, Raloxifene, and Teriparatide for the treatment of osteoporosis. J Clin Densitom. 2014;17(4):490–5.